Bio-Rad Laboratories, Inc.BIONYSE
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank62
3Y CAGR-63.0%
5Y CAGR-19.8%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-63.0%/yr
Quarterly compound
5Y CAGR
-19.8%/yr
Recent deceleration
Percentile
P62
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 36.39% |
| Q3 2025 | 3.78% |
| Q2 2025 | -10.32% |
| Q1 2025 | 4.63% |
| Q4 2024 | -24.12% |
| Q3 2024 | 67.55% |
| Q2 2024 | 39.91% |
| Q1 2024 | -13.89% |
| Q4 2023 | -17.05% |
| Q3 2023 | -0.36% |
| Q2 2023 | -0.05% |
| Q1 2023 | 8.51% |
| Q4 2022 | 719.99% |
| Q3 2022 | -79.30% |
| Q2 2022 | 5.50% |
| Q1 2022 | -68.03% |
| Q4 2021 | -31.45% |
| Q3 2021 | 48.98% |
| Q2 2021 | 36.10% |
| Q1 2021 | -60.10% |
| Q4 2020 | 109.88% |
| Q3 2020 | 47.27% |
| Q2 2020 | 46.67% |
| Q1 2020 | -60.70% |
| Q4 2019 | 60.20% |
| Q3 2019 | -35.81% |
| Q2 2019 | 261.88% |
| Q1 2019 | -59.11% |
| Q4 2018 | 68.62% |
| Q3 2018 | -20.02% |
| Q2 2018 | 92.99% |
| Q1 2018 | -41.83% |
| Q4 2017 | 143.56% |
| Q3 2017 | -54.44% |
| Q2 2017 | 211.20% |
| Q1 2017 | -159.09% |
| Q4 2016 | 84.31% |
| Q3 2016 | -33.11% |
| Q2 2016 | 1135.92% |
| Q1 2016 | -120.72% |